AYTU Quote, Financials, Valuation and Earnings

GeoVax Labs, Inc. has a net margin of 14.15% compared to Aytu Biopharma, Inc.'s net margin of -630.04%. Aytu Biopharma, Inc.'s return on equity of -48.36% beat GeoVax Labs, Inc.'s return on equity of -433.69%.

Aytu Biopharma, Inc. has a consensus price target of $9.33, signalling upside risk potential of 266.01%. On the other hand GeoVax Labs, Inc. has an analysts' consensus of $9.63 which suggests that it could grow by 5945.85%. Given that GeoVax Labs, Inc. has higher upside potential than Aytu Biopharma, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Aytu Biopharma, Inc..

Aytu Biopharma, Inc. has a beta of 0.281, which suggesting that the stock is 71.861% less volatile than S&P 500. In comparison GeoVax Labs, Inc. has a beta of 3.638, suggesting its more volatile than the S&P 500 by 263.848%.

Aytu Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeoVax Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aytu Biopharma, Inc. pays -- of its earnings as a dividend. GeoVax Labs, Inc. pays out -- of its earnings as a dividend.

Aytu Biopharma, Inc. quarterly revenues are $13.9M, which are larger than GeoVax Labs, Inc. quarterly revenues of --. Aytu Biopharma, Inc.'s net income of $2M is higher than GeoVax Labs, Inc.'s net income of -$6.3M. Notably, Aytu Biopharma, Inc.'s price-to-earnings ratio is -- while GeoVax Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aytu Biopharma, Inc. is 0.43x versus 0.69x for GeoVax Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Omeros Corp. has a net margin of 14.15% compared to Aytu Biopharma, Inc.'s net margin of --. Aytu Biopharma, Inc.'s return on equity of -48.36% beat Omeros Corp.'s return on equity of --.

Aytu Biopharma, Inc. has a consensus price target of $9.33, signalling upside risk potential of 266.01%. On the other hand Omeros Corp. has an analysts' consensus of $28.00 which suggests that it could grow by 191.67%. Given that Aytu Biopharma, Inc. has higher upside potential than Omeros Corp., analysts believe Aytu Biopharma, Inc. is more attractive than Omeros Corp..

Aytu Biopharma, Inc. has a beta of 0.281, which suggesting that the stock is 71.861% less volatile than S&P 500. In comparison Omeros Corp. has a beta of 2.485, suggesting its more volatile than the S&P 500 by 148.518%.

Aytu Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aytu Biopharma, Inc. pays -- of its earnings as a dividend. Omeros Corp. pays out -- of its earnings as a dividend.

Aytu Biopharma, Inc. quarterly revenues are $13.9M, which are larger than Omeros Corp. quarterly revenues of --. Aytu Biopharma, Inc.'s net income of $2M is higher than Omeros Corp.'s net income of -$21.2M. Notably, Aytu Biopharma, Inc.'s price-to-earnings ratio is -- while Omeros Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aytu Biopharma, Inc. is 0.43x versus -- for Omeros Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Precigen, Inc. has a net margin of 14.15% compared to Aytu Biopharma, Inc.'s net margin of -5008.35%. Aytu Biopharma, Inc.'s return on equity of -48.36% beat Precigen, Inc.'s return on equity of -711.28%.

Aytu Biopharma, Inc. has a consensus price target of $9.33, signalling upside risk potential of 266.01%. On the other hand Precigen, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 96.76%. Given that Aytu Biopharma, Inc. has higher upside potential than Precigen, Inc., analysts believe Aytu Biopharma, Inc. is more attractive than Precigen, Inc..

Aytu Biopharma, Inc. has a beta of 0.281, which suggesting that the stock is 71.861% less volatile than S&P 500. In comparison Precigen, Inc. has a beta of 1.162, suggesting its more volatile than the S&P 500 by 16.189%.

Aytu Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Precigen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aytu Biopharma, Inc. pays -- of its earnings as a dividend. Precigen, Inc. pays out -- of its earnings as a dividend.

Aytu Biopharma, Inc. quarterly revenues are $13.9M, which are larger than Precigen, Inc. quarterly revenues of $2.9M. Aytu Biopharma, Inc.'s net income of $2M is higher than Precigen, Inc.'s net income of -$146.3M. Notably, Aytu Biopharma, Inc.'s price-to-earnings ratio is -- while Precigen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aytu Biopharma, Inc. is 0.43x versus 203.77x for Precigen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vistagen Therapeutics, Inc. has a net margin of 14.15% compared to Aytu Biopharma, Inc.'s net margin of -7525.97%. Aytu Biopharma, Inc.'s return on equity of -48.36% beat Vistagen Therapeutics, Inc.'s return on equity of -76.57%.

Aytu Biopharma, Inc. has a consensus price target of $9.33, signalling upside risk potential of 266.01%. On the other hand Vistagen Therapeutics, Inc. has an analysts' consensus of $0.97 which suggests that it could grow by 24.28%. Given that Aytu Biopharma, Inc. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe Aytu Biopharma, Inc. is more attractive than Vistagen Therapeutics, Inc..

Aytu Biopharma, Inc. has a beta of 0.281, which suggesting that the stock is 71.861% less volatile than S&P 500. In comparison Vistagen Therapeutics, Inc. has a beta of 0.561, suggesting its less volatile than the S&P 500 by 43.86%.

Aytu Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vistagen Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aytu Biopharma, Inc. pays -- of its earnings as a dividend. Vistagen Therapeutics, Inc. pays out -- of its earnings as a dividend.

Aytu Biopharma, Inc. quarterly revenues are $13.9M, which are larger than Vistagen Therapeutics, Inc. quarterly revenues of $258K. Aytu Biopharma, Inc.'s net income of $2M is higher than Vistagen Therapeutics, Inc.'s net income of -$19.4M. Notably, Aytu Biopharma, Inc.'s price-to-earnings ratio is -- while Vistagen Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aytu Biopharma, Inc. is 0.43x versus 27.30x for Vistagen Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.